Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Pulmonary Tuberculosis | Kisho | Kisho

Back to Pulmonary Tuberculosis

Pulmonary Tuberculosis — NIH Grants & Funding

Active and recent NIH-funded research on Pulmonary Tuberculosis. Data from NIH RePORTER, last 36 months.

MONDO:0006052

NIH-funded research on Pulmonary Tuberculosis

active grants

institutions

131

researchers

new in last 12 mo.

$170.4M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(50)

Basic ScienceR01Active

Macrophage senescence as a driver of granuloma failure and progression to necrosis in TB and TB/HIV

BISHAI, WILLIAM et al.·JOHNS HOPKINS UNIVERSITY·BALTIMORE, MD

$3,145,850 (FY2025)

Pulmonary Tuberculosis — NIH Grants & Funding

Basic Science(50)

Macrophage senescence as a driver of granuloma failure and progression to necrosis in TB and TB/HIV

Immune Regulation in Mycobacterial and Fungal Infections

Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis

A STINGing vaccine for TB

Myeloid and lymphoid immunity-specific mechanisms of IDO mediated immunosuppression and its reversal, during TB

Development of Vaccines to Prevent Tuberculosis

Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis

A tissue-based approach to understanding TB-associated lung fibrosis

Mechanisms of IFNg-independent T cell and B cell-mediated protection in TB.

Human Airway Macrophage Immunity in Tuberculosis: Defining Early Determinants of Infection

Translational(25)

Phase II: Development of Low-Cost, Shelf-Stable Treatment for Tuberculosis

Deep spatial immune profiling of granulomas and M. tuberculosis adaptation to disease and treatment

Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine

Teixobactin Development for Tuberculosis

Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis

Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance

Manipulation of the host cell inflammasome by Mycobacterium tuberculosis

Optimizing vaccine science to improve the outcome of tuberculosis treatment

Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis

Eliciting Th1/Th17 dual responses for vaccine-induced immunity to tuberculosis

Clinical(14)

C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study

The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis

Short-course rifapentine for TB prevention for all: clinical pharmacology matters

Hypoxia, tuberculosis, and T cell dysfunction

PET to Assess Post-TB Lung Disease in TB Patients with / without HIV coinfection

Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS)

Non-tuberculous mycobacterium and B cells in the stimulation of ectopic germinal centers and immunological control of pulmonary tuberculosis

Identifying patients at risk of post-tuberculosis lung disease using novel cough and adherence predictors

Targeted Implementation of Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease

Impact of SARS-CoV-2 infection on reactivation of latent Mtb infections in a Kenyan Cohort

Epi / Nat. History(19)

Post-Tuberculosis Lung Disease in Youth with and without HIV Globally

Sex, HIV, and Air Pollution Effects on Post-TB Lung Disease (SHAPE PTLD)

Causality of Post-TB Lung Disease: Population-Level Evidence from Rural Uganda

Host- and pathogen-specific risk factors for post-tuberculosis lung disease among people successfully treated for TB in Lima, Peru: Beat-PTLD

Causality of Post-TB Lung Disease: Population-Level Evidence from Rural Uganda

Improving Native American Health Through Community-based Screening and Diagnostic Testing for Tuberculosis

Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study

Heart and Lung Outcomes Post-TB (HALO Post-TB)

Impact of TB coinfection on HIV reservoir

Post-Tuberculosis Lung Disease in Youth with and without HIV Globally

Biomarker / Dx(13)

Fibroblast activating protein PET-CT imaging of TB-associated fibrosis

Novel Pediatric TB Diagnostics using Host and Microbial Biomarkers

Leveraging antibody-omics to prevent and detect TB in children affected by HIV

Tuberculosis in Malawian children under five years old: exploring non-invasive diagnostic strategies and the impact of malnutrition on treatment pharmacokinetics

Automated lung sound analysis to improve the clinical diagnosis of pulmonary tuberculosis in children

Lung Ultrasound and Artificial Intelligence Technology for the Diagnosis of TB in LMICs

Predicting tuberculosis outcomes using genotypic and biomarker signatures

An Antigen-Detection Blood Test for Pulmonary Tuberculosis

Early and accurate diagnosis of pulmonary and extrapulmonary tuberculosis in all patient groups using a circulating pathogen-derived antigen

Non-invasive diagnosis of adult pulmonary tuberculosis

Medical Device(2)

Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker

[R21] Integrated computer-aided, point-of-care ultrasound for tuberculosis screening

Other(9)

Novel Stem Cell Immunotherapy for MDR-Tuberculosis

Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis”

Functional Definition of T Cell Receptors Associated with Protection from Pulmonary TB Infection and Disease

Durability of systemic and lung immune correlates of BCG-induced protection against M. tuberculosis infection

Molecular mechanisms of MCP-1 polymorphism-mediated susceptibility to pulmonary tuberculosis infection

Targeted Implementation of Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease

Pulmonary Innate Immunity & Resistance to Mycobacterium Tuberculosis Infection

Host Proteomic Biosignatures for a Urine-based Diagnosis of Pulmonary Tuberculosis in Children

Investigation of responses to Mycobacterium tuberculosis complex lineages by different African host population: Implications for host-directed therapies